A Phase 2 interventional study of CORT125134 in Cushing's Syndrome, sponsored by Corcept Therapeutics. Completed at 25 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-10-15.
Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Cushing Syndrome by Corcept Therapeutics — none open to participants now, 1 under way, none of them phase 3. Cushing Syndrome · Corcept Therapeutics.
Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2016, is one of 2 in phase 2, and was the 7th registered.
123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.
Browse Cushing Syndrome studies →None of the 16 studies in Cushing Syndrome by Corcept Therapeutics is open now. The open studies under Cushing Syndrome, anywhere →
Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2016.
This study's enrollment of 35 is below the median of 44 across 58 interventional studies indexed under Cushing Syndrome.
Median enrollment 35 across the 11 interventional studies, 24 across the 5 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.
1 of the studies in Cushing Syndrome by Corcept Therapeutics that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol.
Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, were not eligible for enrollment in this study.
The purpose of this study was to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study was conducted in the United States and in Europe.
This was a Phase 2, open-label study with two dose groups, each with a two-step dose escalation, designed to evaluate the safety and efficacy of CORT125134 for the treatment of endogenous Cushing's syndrome. CORT125134 was administered orally once daily for 16 weeks with dose escalations occurring every 4 weeks.
Pharmacokinetics (PK) profiles were generated at every dose level. A data review committee reviewed PK and safety data and recommended the final plan for dose escalation in Group 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets at least one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
Drug: CORT125134
250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.
Drug: CORT125134
Percentage of Participants With One or More Adverse Events
All treatment-emergent adverse events were recorded and summarized.
Time frame: Group 1: up to Week 16; Group 2: up to Week 20
Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events
All treatment-emergent adverse events with Common Terminology Criteria for Adverse Events (CTCAE) ≥Grade 3 (severe) were recorded and summarized.
Time frame: Group 1: up to Week 16; Group 2: up to Week 20
Percentage of Participants With Hypertension Who Experience Improvement in Blood Pressure Following Treatment With CORT125134
Improvement in blood pressure was defined as a participant who experiences at least a 5 mmHg decrease in mean diastolic or systolic BP from baseline who has not taken an additional antihypertensive medication during the treatment period or increased the dosage of a concurrent antihypertensive medication.
Time frame: Group 1: Week 12 or last observation; Group 2: Week 16 or last observation
Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134
Improvement in glucose control was defined as a participant who experiences at least a 25% decrease from baseline in area under the concentration-time curve for blood glucose (AUCglucose) who has not taken an additional diabetes medication during the treatment period or increased the dosage of a concurrent diabetes medication.
Time frame: Before and 0.5, 1, 1.5, and 2 hours after a glucose drink at Week 12 or last observation (Group 1) or Week 16 or last observation (Group 2)
All enrolled participants who received at least 1 dose of study drug
| Milestone | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Started | 17 | 18 |
| Completed | 17 | 15 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Started | 17 | 15 |
| Completed | 16 | 15 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Started | 16 | 15 |
| Completed | 16 | 13 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 2 |
| Milestone | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Started | 0 | 12 |
| Completed | 0 | 7 |
| Not completed | 0 | 5 |
| Withdrew: Adverse event | 0 | 5 |
All treatment-emergent adverse events were recorded and summarized.
| Participants | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Percentage of Participants With One or More Adverse Events | 15 | 18 |
All treatment-emergent adverse events with Common Terminology Criteria for Adverse Events (CTCAE) ≥Grade 3 (severe) were recorded and summarized.
| Participants | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events | 3 | 7 |
Improvement in blood pressure was defined as a participant who experiences at least a 5 mmHg decrease in mean diastolic or systolic BP from baseline who has not taken an additional antihypertensive medication during the treatment period or increased the dosage of a concurrent antihypertensive medication.
| Percentage of participants | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Percentage of Participants With Hypertension Who Experience Improvement in Blood Pressure Following Treatment With CORT125134 | 41.67 (15.17 to 72.33) | 63.64 (30.79 to 89.07) |
Improvement in glucose control was defined as a participant who experiences at least a 25% decrease from baseline in area under the concentration-time curve for blood glucose (AUCglucose) who has not taken an additional diabetes medication during the treatment period or increased the dosage of a concurrent diabetes medication.
| Percentage of participants | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134 | 23.08 (5.04 to 53.81) | 0 (0 to 23.16) |
Improvement in glucose control was defined based on response criteria for Phase 3 study NCT03697109: a participant who experiences 1) a hemoglobin A1c (HbA1c) that is decreased by ≥ 0.5% from baseline, 2) a 2-hour oGTT plasma glucose that is normalized (\< 7.8 mmol/L) or decreased by ≥ 2.8 mmol/L from baseline, or 3) a total daily insulin dose that has decreased by ≥ 25% or total daily sulfonylurea dose that has decreased by ≥ 50% and an HbA1c that is unchanged or decreased from baseline.
| Percentage of participants | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Percentage of Participants With IGT / T2DM Who Experienced Improvement in Glucose Control Following Treatment With CORT125134: Responder Definition Based on Response Criteria for Phase 3 Study NCT03697109 | 15.38 (1.92 to 45.45) | 50.00 (21.09 to 78.91) |
Collected over Group 1: up to Week 16; Group 2: up to Week 20. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Low-dose Group | 0/17 (0%) | 0/17 (0%) | 15/17 (88.2%) |
| Group 2: High-dose Group | 0/18 (0%) | 4/18 (22.2%) | 18/18 (100%) |
| Event | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Pilonidal cystInfections and infestations | 0/17 | 1/18 |
| MyopathyMusculoskeletal and connective tissue disorders | 0/17 | 1/18 |
| Acute myocardial infarctionCardiac disorders | 0/17 | 1/18 |
| HypertensionVascular disorders | 0/17 | 1/18 |
| PolyneuropathyNervous system disorders | 0/17 | 1/18 |
| Event | Group 1: Low-dose Group | Group 2: High-dose Group |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 4/17 | 7/18 |
| NauseaGastrointestinal disorders | 3/17 | 5/18 |
| Oedema peripheralGeneral disorders | 4/17 | 5/18 |
| HeadacheNervous system disorders | 4/17 | 5/18 |
| DiarrhoeaGastrointestinal disorders | 4/17 | 3/18 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/17 | 4/18 |
| DyspepsiaGastrointestinal disorders | 1/17 | 4/18 |
| Abdominal painGastrointestinal disorders | 0/17 | 4/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/17 | 4/18 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/17 | 4/18 |
All enrolled participants who received at least 1 dose of study drug
| Age, Continuous(years) | Group 1: Low-dose Group | Group 2: High-dose Group | Total |
|---|---|---|---|
| Mean | 47.6 ± 13.62 | 49.5 ± 13.46 | 48.6 ± 13.37 |
| Sex: Female, Male(Participants) | Group 1: Low-dose Group | Group 2: High-dose Group | Total |
|---|---|---|---|
| Female | 9 | 16 | 25 |
| Male | 8 | 2 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Low-dose Group | Group 2: High-dose Group | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 16 | 16 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: Low-dose Group | Group 2: High-dose Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 17 | 18 | 35 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Group 1: Low-dose Group | Group 2: High-dose Group | Total |
|---|---|---|---|
| Netherlands | 2 | 0 | 2 |
| Hungary | 3 | 2 | 5 |
| United States | 3 | 9 | 12 |
| Italy | 7 | 7 | 14 |
| United Kingdom | 2 | 0 | 2 |
| Hypertension(Participants) | Group 1: Low-dose Group | Group 2: High-dose Group | Total |
|---|---|---|---|
| Count of participants | 12 | 11 | 23 |
| Impaired Glucose Tolerance (IGT) / Type-2 Diabetes Mellitus (T2DM)(Participants) | Group 1: Low-dose Group | Group 2: High-dose Group | Total |
|---|---|---|---|
| Count of participants | 13 | 15 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2016 to primary completion in Sep 2018, 27 months.
Results were first posted in Sep 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relacorilant